When compared to Medicare Advantage and Medicare Fee-for-Service benchmarks, Medicare Advantage patients with diabetes in the agilon model experienced improvements in Hemoglobin A1c control and other metrics that were 2-3 times larger.
Statistics show decreased expenditures for diabetic patients with constant Hemoglobin A1c management.
Medically underserved areas are also eligible for benefits.
Texas's AUSTIN—(BUSINESS WIRE)— New data analysing the effects of the full-risk Total Care Model (agilon model) among Medicare Advantage (MA) patients with diabetes has been released by agilon health, inc. (NYSE: AGL), the trusted partner empowering physicians to revolutionise health care in our communities.
Overall, the analysis revealed that patients with diabetes treated by agilon's physician partners outperform all Medicare and MA Fee-for-Service (FFS) benchmarks, leading to better health outcomes and a significant decrease in both out-of-pocket and systemwide costs for patients with consistently controlled diabetes.Additionally, the investigation discovered that similar advantages also apply to diabetic patients who receive care using the agilon model and reside in Medically Underserved Areas (MUAs). Additionally, the investigation discovered that similar advantages also apply to diabetic patients who receive care using the agilon model and reside in Medically Underserved Areas (MUAs).
According to Steve Sell, chief executive officer of agilon health, "these findings underline agilon's objective to develop a healthcare system that works better for both primary care physicians and senior patients." Agilon's medical partners are significantly improving the lives of their senior diabetic patients and, as a result, the communities in which they live. This is accomplished by prioritising quality of care over quantity of services. We are devoted to promoting health equity, and we are pleased that these statistics demonstrate that individuals in medically underserved areas are receiving the same, superior treatment as elders in other regions.
"Dr. Benjamin Kornitzer, chief medical & quality officer, agilon health, stated that "one in four American seniors live with diabetes, which means that diabetes touches nearly every American family in some way." "A diagnosis of diabetes can drastically affect a patient's life and result in severe emotional and financial hardship. In agilon's Total Care Model, primary care professionals are in a unique position to assist patients prevent the crippling effects of diabetes, such as kidney failure, eyesight loss, heart attacks, and strokes, among other things. Based on CMS diabetes Star Rating standards, these results confirm that agilon's physician partners deliver best-in-class quality treatment and resulted in significant cost savings for patients and the regional healthcare system."
Nearly 500,000 seniors, including 112,000 people with diabetes, are under the whole quality and financial responsibility of agilon's medical partners. The data in the analysis looked at the treatment of diabetic patients who satisfied the Centers for Medicare & Medicaid Services' (CMS) inclusion requirements for Hemoglobin A1c (HbA1c) management and eye exams in 2020 and 2021.
In that time, the agilon model's HbA1c control for diabetic patients rose from 81% to 88%. This rise was 3.8 times bigger than CMS' multi-payor Comprehensive Primary Care Plus (CPC+), which is regarded as the gold standard for FFS model benchmarking, and was 2.1 times better than the rate of improvement for all MA patients from 2020 to 2021. Moreover, the percentage of diabetic patients in the agilon model who underwent an eye exam increased from 72% to 80%, which is 3.2 times greater than the development CMS recorded for all MA patients during this time.
The investigation also revealed that the agilon model significantly lowers the cost of diabetes care for patients as well as the healthcare system. The total cost of care was 19% cheaper for patients in the agilon model with consistently managed HbA1c levels in 2020 and 2021 compared to MA patients who were unable to show control in either one or both of those years. These savings resulted in a direct 19% decrease in patients' out-of-pocket expenses. Additionally, compared to patients who did not show evidence of control in both years, patients in the agilon model with consistently controlled HbA1c had 47% fewer acute inpatient admissions, 65% fewer potentially avoidable admissions for any reason, and 84% fewer diabetes-related avoidable admissions.
Additionally, these data demonstrate how agilon's methodology is enhancing health equity for diabetic patients. According to the investigation, individuals with diabetes in the agilon model who reside in MUAs (28%) received care that was on par with or better than that provided to patients in other parts of the country. Notably, compared to patients in other locations, patients in MUAs had 2% more annual wellness visits and 8% more annual primary care visits. Additionally, patients in MUAs had comparable HbA1c management to those in other regions and saw fewer hospitalisations, unnecessary admissions, and ER visits.
Additional Details:
- As the U.S. population ages, the prevalence of diabetes among seniors over 65 is predicted to increase to one in four.
- In the US, diabetes is the fifth most common cause of mortality.
- Diabetes is the major cause of kidney failure, lower limb amputations, adult blindness, and increases the risk of heart attacks and strokes in adults by a factor of two.
- One out of every four healthcare dollars spent in the US goes toward treating diabetic patients, whose typical medical expenses are more than twice as high as those of non-diabetics.
0 Comments